Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).

被引：48
|
作者：
Sharma, Padmanee
Pachynski, Russell Kent
Narayan, Vivek
Flechon, Aude
Gravis, Gwenaelle
Galsky, Matt D.
Mahammedi, Hakim
Patnaik, Akash
Subudhi, Sumit Kumar
Ciprotti, Marika
Duan, Tao
Saci, Abdel
Hu, Sarah
Han, G. Celine
Fizazi, Karim
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] Penn Med Abramson Canc Ctr, Philadelphia, PA USA
[4] Ctr Leon Berard, Lyon, France
[5] Inst Paoli Calmettes, Med Oncol, Marseille, France
[6] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA
[7] Ctr Jean Perrin, Clermont Ferrand, France
[8] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA
[9] Bristol Myers Squibb, Princeton, NJ USA
[10] Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.142
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
142
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Initial Results From a Phase 2 Study of Nivolumab Plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 8 - 10
  • [2] Evaluating nivolumab (nivo) plus ipilimumab (ipi) in patients with metastatic castration-resistant prostate cancer (mCRPC): Clinical and translational results from the AMADEUS prostate expansion cohort
    Tsimberidou, Apostolia M.
    Drakaki, Alexandra
    Khalil, Danny N.
    Okrah, Kwame
    Schachter, Mike
    Gautam, Shikha
    Da Silva, Diane M.
    Alayli, Farah A.
    Spencer, Christine N.
    Foo, Wai Chin
    Adamow, Matthew
    Wong, Phillip
    Fairchild, Justin
    Arnott, Jamie
    Dugan, Ute
    Boffo, Silvia
    Salvador, Lisa
    Cabanski, Christopher R.
    Subudhi, Sumit K.
    Sharma, Padmanee
    CANCER RESEARCH, 2024, 84 (07)
  • [3] Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial.
    Sharma, Padmanee
    Krainer, Michael
    Saad, Fred
    Castellano, Daniel
    Bedke, Jens
    Kwiatkowski, Mariusz
    Patnaik, Akash
    Procopio, Giuseppe
    Wiechno, Pawel
    Kochuparambil, Samith Thomas
    Thomas, Christian
    Arija, Jose Angel Arranz
    McCune, Steven L.
    Hansen, Steinbjorn
    Daugaard, Gedske
    Amin, Neha P.
    Wang, Yumeng
    David, Justin M.
    Pachynski, Russell Kent
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [4] Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
    Sharma, Padmanee
    Pachynski, Russell K.
    Narayan, Vivek
    Flechon, Aude
    Gravis, Gwenaelle
    Galsky, Matthew D.
    Mahammedi, Hakim
    Patnaik, Akash
    Subudhi, Sumit K.
    Ciprotti, Marika
    Simsek, Burcin
    Saci, Abdel
    Hu, Yanhua
    Han, G. Celine
    Fizazi, Karim
    CANCER CELL, 2020, 38 (04) : 489 - +
  • [5] Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Slovin, S. F.
    Beer, T. M.
    Higano, C. S.
    Tejwani, S.
    Hamid, O.
    Picus, J.
    Harzstark, A.
    Scher, H. I.
    Lan, Z.
    Lowy, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Phase II Study with metastatic castration-resistant Prostate Cancer (mCRPC) Patients
    Rexer, H.
    Graefen, M.
    UROLOGE, 2017, 56 (11): : 1468 - 1470
  • [7] Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.
    Tawbi, Hussein Abdul-Hassan
    Forsyth, Peter A. J.
    Algazi, Alain Patrick
    Hamid, Omid
    Hodi, F. Stephen
    Moschos, Stergios J.
    Khushalani, Nikhil I.
    Gonzalez, Rene
    Lao, Christopher D.
    Postow, Michael Andrew
    Atkins, Michael B.
    Ernstoff, Marc S.
    Puzanov, Igor
    Kudchadkar, Ragini Reiney
    Thomas, Reena Parada
    Tarhini, Ahmad A.
    Jiang, Joel
    Avila, Alexandre
    Demelo, Sheena
    Margolin, Kim Allyson
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
    Fizazi, Karim
    Retz, Margitta
    Petrylak, Daniel P.
    Goh, Jeffrey C.
    Perez-Gracia, Jose
    Lacombe, Louis
    Zschabitz, Stefanie
    Burotto, Mauricio
    Mahammedi, Hakim
    Gravis, Gwenaelle
    Bastos, Diogo Assed
    McCune, Steven L.
    Limon, Juan Carlos Vazquez
    Kwan, Edmond M.
    Castellano, Daniel
    Flechon, Aude
    Saad, Fred
    Grimm, Marc-Oliver
    Shaffer, David R.
    Armstrong, Andrew J.
    Bhagavatheeswaran, Prabhu
    Amin, Neha P.
    Unsal-Kacmaz, Keziban
    Wang, Xuya
    Li, Jun
    Loehr, Andrea
    Pachynski, Russell K.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (08)
  • [9] Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC).
    Boudadi, Karim
    Suzman, Daniel L.
    Luber, Brandon
    Wang, Hao
    Silberstein, John
    Sullivan, Rana
    Dowling, Donna
    Harb, Rana
    Nirschl, Thomas
    Dittamore, Ryan Vance
    Carducci, Michael Anthony
    Eisenberger, Mario A.
    Haffner, Michael
    Meeker, Alan
    Eshleman, James R.
    Luo, Jun
    Drake, Charles G.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Phase II study of cabazitaxel (CAB) plus enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC)
    Graff, Julie Nicole
    Cheng, Heather H.
    Vuky, Jacqueline
    Alumkal, Joshi J.
    Kreitner, Dustin
    Petreaca, Delia
    Grivas, Petros
    Schweizer, Michael Thomas
    Higano, Celestia S.
    Chen, Yiyi
    Yu, Evan Y.
    Beer, Tomasz M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345